For the year ending 2025-12-31, KYMR made $39,211K in revenue. -$308,066K in net income. Net profit margin of -785.66%.
| Income Statement | 2025-12-31 | 2024-12-31 | ||
|---|---|---|---|---|
| Collaboration revenue | 39,211 | 47,072 | ||
| Research and development | 316,568 | 240,248 | ||
| General and administrative | 68,187 | 63,534 | ||
| Impairment of long-lived assets | 3,855 | 4,925 | ||
| Total operating expenses | 388,610 | 308,707 | ||
| Loss from operations | -349,399 | -261,635 | ||
| Interest and other income | 38,418 | 38,026 | ||
| Interest and other expense | 370 | 249 | ||
| Total other income | 38,048 | 37,777 | ||
| Net loss | -311,351 | -223,858 | ||
| Unrealized gain (loss) on marketable securities | 3,285 | -933 | ||
| Total comprehensive loss | -308,066 | -224,791 | ||
| Basic EPS | -3.69 | -2.98 | ||
| Diluted EPS | -3.69 | -2.98 | ||
| Basic Average Shares | 84,490,585 | 75,043,991 | ||
| Diluted Average Shares | 84,490,585 | 75,043,991 | ||
Kymera Therapeutics, Inc. (KYMR)
Kymera Therapeutics, Inc. (KYMR)